ERBB2 and neoplasm: HER2 amplification (2–5%) and RAS–MAPK pathway mutations (e.g., KRAS G12D, BRAF V600E) further drive resistance, while PI3K pathway activation via PIK3CA mutations or PTEN loss promotes tumor survival.